ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours

详细信息    查看全文

• 作者：Annica Wilzén (1)
  Cecilia Krona (2)
  Baldur Sveinbj?rnsson (2) (3)
  Erik Kristiansson (4)
  Daniel Dalevi (4)
  Ingrid ?ra (5)
  Katleen De Preter (6)
  Raymond L Stallings (7)
  John Maris (8)
  Rogier Versteeg (9)
  Staffan Nilsson (4)
  Per Kogner (2)
  Frida Abel (1)
  
• 关键词：Microarray ; Expression ; Cancer ; Systems biology ; Oncology ; Network ; Reverse engineering ; Unsupervised ; Clustering ; Cell cycle ; Spindle assembly ; Her ; 3 ; HER3 ; ERBB3 ; Her ; 2 ; HER2 ; ERBB2 ; EGFR ; ERBB1 ; BIRC5 ; Survivin ; MYCN ; N ; myc ; ALK ; PHOX2B ; NTRK1 ; CCND1
• 刊名：Molecular Cancer
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：12
• 期：1
• 全文大小：1413KB
• 参考文献：1. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B: Terminology and morphologic criteria of neuroblastic tumors: recommendations by the international Neuroblastoma pathology committee. / Cancer 1999, 86:349-63. CrossRef
  2. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, / et al.: Revisions of the international criteria for Neuroblastoma diagnosis, staging, and response to treatment. / J Clin Oncol 1993, 11:1466-477.
  3. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, / et al.: The international Neuroblastoma risk group (INRG) staging system: an INRG task force report. / J Clin Oncol 2009, 27:298-03. CrossRef
  4. Breslow N, McCann B: Statistical estimation of prognosis for children with Neuroblastoma. / Cancer Res 1971, 31:2098-103.
  5. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP: The international Neuroblastoma pathology classification (the shimada system). / Cancer 1999, 86:364-72. CrossRef
  6. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM: Amplification of N-myc in untreated human Neuroblastoma correlates with advanced disease stage. / Science 1984, 224:1121-124. CrossRef
  7. Caren H, Kryh H, Nethander M, Sjoberg RM, Trager C, Nilsson S, Abrahamsson J, Kogner P, Martinsson T: High-risk Neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. / Proc Natl Acad Sci USA 2010, 107:4323-328. CrossRef
  8. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, Smith EI, Brodeur GM: Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood Neuroblastoma: a pediatric oncology group study. / J Clin Oncol 1991, 9:581-91.
  9. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, / et al.: The international Neuroblastoma risk group (INRG) classification system: an INRG task force report. / J Clin Oncol 2009, 27:289-97. CrossRef
  10. Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. / Nat Rev Cancer 2003, 3:203-16. CrossRef
  11. Michels E, Vandesompele J, De Preter K, Hoebeeck J, Vermeulen J, Schramm A, Molenaar JJ, Menten B, Marques B, Stallings RL, / et al.: ArrayCGH-based classification of Neuroblastoma into genomic subgroups. / Genes Chromosomes Cancer 2007, 46:1098-108. CrossRef
  12. Abel F, Dalevi D, Nethander M, Jornsten R, De Preter K, Vermeulen J, Stallings R, Kogner P, Maris J, Nilsson S: A 6-gene signature identifies four molecular subgroups of Neuroblastoma. / Cancer cell international 2011, 11:9. CrossRef
  13. Buckley PG, Alcock L, Bryan K, Bray I, Schulte JH, Schramm A, Eggert A, Mestdagh P, De Preter K, Vandesompele J, / et al.: Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- Neuroblastoma. / Clin Cancer Res 2010, 16:2971-978. CrossRef
  14. De Preter K, De Brouwer S, Van Maerken T, Pattyn F, Schramm A, Eggert A, Vandesompele J, Speleman F: Meta-mining of Neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds. / Clin Cancer Res 2009, 15:3690-696. CrossRef
  15. De Preter K, Mestdagh P, Vermeulen J, Zeka F, Naranjo A, Bray I, Castel V, Chen C, Drozynska E, Eggert A, / et al.: miRNA expression profiling enables risk stratification in archived and fresh Neuroblastoma tumor samples. / Clin Cancer Res 2011, 17:7684-692. CrossRef
  16. De Preter K, Vermeulen J, Brors B, Delattre O, Eggert A, Fischer M, Janoueix-Lerosey I, Lavarino C, Maris JM, Mora J, / et al.: Accurate outcome prediction in Neuroblastoma across independent data sets using a multigene signature. / Clin Cancer Res 2010, 16:1532-541. CrossRef
  17. Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, Asgharzadeh S, Seeger R, Scaruffi P, Tonini GP, / et al.: Prognostic impact of gene expression-based classification for Neuroblastoma. / J Clin Oncol 2010, 28:3506-515. CrossRef
  18. Schulte JH, Schowe B, Mestdagh P, Kaderali L, Kalaghatgi P, Schlierf S, Vermeulen J, Brockmeyer B, Pajtler K, Thor T, / et al.: Accurate prediction of Neuroblastoma outcome based on miRNA expression profiles. / Int J Cancer 2010, 127:2374-385. CrossRef
  19. Vermeulen J, De Preter K, Laureys G, Speleman F, Vandesompele J: 59-gene prognostic signature sub-stratifies high-risk Neuroblastoma patients. / Lancet Oncol 2009, 10:1030. CrossRef
  20. Molenaar JJ, Koster J, Ebus ME, van Sluis P, Westerhout EM, de Preter K, Gisselsson D, Ora I, Speleman F, Caron HN, Versteeg R: Copy number defects of G1-cell cycle genes in Neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. / Genes Chromosomes Cancer 2012, 51:10-9. CrossRef
  21. Valentijn LJ, Koster J, Haneveld F, Aissa RA, van Sluis P, Broekmans ME, Molenaar JJ, van Nes J, Versteeg R: Functional MYCN signature predicts outcome of Neuroblastoma irrespective of MYCN amplification. / Proc Natl Acad Sci USA 2012, 109:19190-9195. CrossRef
  22. Caren H, Abel F, Kogner P, Martinsson T: High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic Neuroblastoma tumours. / Biochem J 2008, 416:153-59. CrossRef
  23. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, / et al.: Meta-analysis of Neuroblastoma reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. / Clin Cancer Res 2010, 16:4353-362. CrossRef
  24. Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, Gregorio A, Gambini C, Garaventa A, Pistoia V, / et al.: Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis Neuroblastoma patients. / Cancer Res 2009, 69:7338-346. CrossRef
  25. Sithanandam G, Anderson LM: The ERBB3 receptor in cancer and cancer gene therapy. / Cancer Gene Ther 2008, 15:413-48. CrossRef
  26. Margolin AA, Wang K, Lim WK, Kustagi M, Nemenman I, Califano A: Reverse engineering cellular networks. / Nat Protoc 2006, 1:662-71. CrossRef
  27. Allen JD, Xie Y, Chen M, Girard L, Xiao G: Comparing statistical methods for constructing large scale gene networks. / PLoS One 2012, 7:e29348. CrossRef
  28. Lamers F, van der Ploeg I, Schild L, Ebus ME, Koster J, Hansen BR, Koch T, Versteeg R, Caron HN, Molenaar JJ: Knockdown of surviving (BIRC5) causes apoptosis in Neuroblastoma via mitotic catastrophe. / Endocr-Related Cancer 2011, 18:657-68. CrossRef
  29. Katoh M, Igarashi M, Fukuda H, Nakagama H, Katoh M: Cancer genetics and genomics of human FOX family genes. / Cancer Lett 2013, 328:198-06. CrossRef
  30. Eckerle I, Muth D, Batzler J, Henrich KO, Lutz W, Fischer M, Witt O, Schwab M, Westermann F: Regulation of BIRC5 and its isoform BIRC5-B in Neuroblastoma. / Cancer Lett 2009, 285:99-07. CrossRef
  31. Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R, Christiansen H, / et al.: Stabilization of N-Myc is a critical function of Aurora A in human Neuroblastoma. / Cancer cell 2009, 15:67-8. CrossRef
  32. Munirajan AK, Ando K, Mukai A, Takahashi M, Suenaga Y, Ohira M, Koda T, Hirota T, Ozaki T, Nakagawara A: KIF1Bbeta functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2 by inducing apoptotic cell death. / J Biol Chem 2008, 283:24426-4434. CrossRef
  33. Schlisio S, Kenchappa RS, Vredeveld LC, George RE, Stewart R, Greulich H, Shahriari K, Nguyen NV, Pigny P, Dahia PL, / et al.: The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. / Genes Dev 2008, 22:884-93. CrossRef
  34. Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, Kim J, Zhao H, Pawel BR, London WB, / et al.: CHD5, a tumor suppressor gene deleted from 1p36.31 in Neuroblastoma. / J Natl Cancer Inst 2008, 100:940-49. CrossRef
  35. Brodeur GM, Fong CT, Morita M, Griffith R, Hayes FA, Seeger RC: Molecular analysis and clinical significance of N-myc amplification and chromosome 1p monosomy in human Neuroblastoma. / Prog Clin Biol Res 1988, 271:3-5.
  36. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, / et al.: Sequencing of Neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. / Nature 2012, 483:589-93. CrossRef
  37. Mocellin S, Zavagno G, Nitti D: The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. / Int J Cancer 2008, 123:2370-376. CrossRef
  38. Levy P, Vidaud D, Leroy K, Laurendeau I, Wechsler J, Bolasco G, Parfait B, Wolkenstein P, Vidaud M, Bieche I: Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. / Mol Cancer 2004, 3:20. CrossRef
  39. Satge D, Sasco AJ, Carlsen NL, Stiller CA, Rubie H, Hero B, de Bernardi B, de Kraker J, Coze C, Kogner P, / et al.: A lack of Neuroblastoma in Down syndrome: a study from 11 European countries. / Cancer Res 1998, 58:448-52.
  40. Britsch S, Goerich DE, Riethmacher D, Peirano RI, Rossner M, Nave KA, Birchmeier C, Wegner M: The transcription factor Sox10 is a key regulator of peripheral glial development. / Genes Dev 2001, 15:66-8. CrossRef
  41. Buac K, Watkins-Chow DE, Loftus SK, Larson DM, Incao A, Gibney G, Pavan WJ: A Sox10 expression screen identifies an amino acid essential for Erbb3 function. / PLoS Genet 2008, 4:e1000177. CrossRef
  42. Addo-Yobo SO, Straessle J, Anwar A, Donson AM, Kleinschmidt-Demasters BK, Foreman NK: Paired overexpression of ErbB3 and Sox10 in pilocytic astrocytoma. / J Neuropathol Exp Neurol 2006, 65:769-75. CrossRef
  43. Karamchandani JR, Nielsen TO, van de Rijn M, West RB: Sox10 and S100 in the diagnosis of soft-tissue neoplasms. / Appl Immunohistochem Mol Morphol 2012, 20:445-50. CrossRef
  44. Acosta S, Lavarino C, Paris R, Garcia I, de Torres C, Rodriguez E, Beleta H, Mora J: Comprehensive characterization of Neuroblastoma cell line subtypes reveals bilineage potential similar to neural crest stem cells. / BMC Dev Biol 2009, 9:12. CrossRef
  45. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE: The ErbB2/ErbB3 heterodimers functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. / Proc Natl Acad Sci USA 2003, 100:8933-938. CrossRef
  46. Ho R, Minturn JE, Hishiki T, Zhao H, Wang Q, Cnaan A, Maris J, Evans AE, Brodeur GM: Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. / Cancer Res 2005, 65:9868-875. CrossRef
  47. Hua Y, Gorshkov K, Yang Y, Wang W, Zhang N, Hughes DP: Slow down to stay alive: HER4 protects against cellular stress and confers chemo resistance in Neuroblastoma. / Cancer 2012, 118:5140-154. CrossRef
  48. Izycka-Swieszewska E, Wozniak A, Drozynska E, Kot J, Grajkowska W, Klepacka T, Perek D, Koltan S, Bien E, Limon J: Expression and significance of HER family receptors in neuroblastic tumors. / Clin Exp Metastas 2011, 28:271-82. CrossRef
  49. Peuchmaur M, d'Amore ES, Joshi VV, Hata J, Roald B, Dehner LP, Gerbing RB, Stram DO, Lukens JN, Matthay KK, Shimada H: Revision of the international Neuroblastoma pathology classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. / Cancer 2003, 98:2274-281. CrossRef
  50. Van Ho AT, Hayashi S, Brohl D, Aurade F, Rattenbach R, Relaix F: Neural crest cell lineage restricts skeletal muscle progenitor cell differentiation through Neuregulin1-ErbB3 signaling. / Dev Cell 2011, 21:273-87. CrossRef
  51. Izycka-Swieszewska E, Wozniak A, Kot J, Grajkowska W, Balcerska A, Perek D, Dembowska-Baginska B, Klepacka T, Drozynska E: Prognostic significance of HER2 expression in neuroblastic tumors. / Mod Pathol 2010, 23:1261-268. CrossRef
  52. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, / et al.: Bio conductor: open software development for computational biology and bioinformatics. / Genome Biol 2004, 5:R80. CrossRef
  53. De Preter K, Vandesompele J, Heimann P, Yigit N, Beckman S, Schramm A, Eggert A, Stallings RL, Benoit Y, Renard M, / et al.: Human fetal neuroblast and Neuroblastoma transcriptome analysis confirms neuroblast origin and highlights Neuroblastoma candidate genes. / Genome Biol 2006, 7:R84. CrossRef
  54. McArdle L, McDermott M, Purcell R, Grehan D, O'Meara A, Breatnach F, Catchpoole D, Culhane AC, Jeffery I, Gallagher WM, Stallings RL: Oligonucleotide microarray analysis of gene expression in Neuroblastoma displaying loss of chromosome 11q. / Carcinogenesis 2004, 25:1599-609. CrossRef
  55. Wilzén A, Nilsson S, Sjoberg R, Martinsson T, Abel F: The Phox2 pathway is suppressed in high risk Neuroblastoma tumors, but does not involve mutations of the candidate tumor suppressor gene PHOX2A. 2008.
  56. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, Seiser E, Jagannathan J, Shusterman S, Bansal M, / et al.: Integrative genomics identifies distinct molecular classes of Neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. / Cancer Res 2006, 66:6050-062. CrossRef
  57. Revet I, Huizenga G, Chan A, Koster J, Volckmann R, van Sluis P, Ora I, Versteeg R, Geerts D: The MSX1 home box transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in Neuroblastoma. / Exp Cell Res 2008, 314:707-19. CrossRef
  58. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. / Proc Natl Acad Sci USA 2001, 98:5116-121. CrossRef
  59. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. / Proc Natl Acad Sci USA 2005, 102:15545-5550. CrossRef
  
• 作者单位：Annica Wilzén (1)
  Cecilia Krona (2)
  Baldur Sveinbj?rnsson (2) (3)
  Erik Kristiansson (4)
  Daniel Dalevi (4)
  Ingrid ?ra (5)
  Katleen De Preter (6)
  Raymond L Stallings (7)
  John Maris (8)
  Rogier Versteeg (9)
  Staffan Nilsson (4)
  Per Kogner (2)
  Frida Abel (1)
  
  1. Department of Clinical Genetics, Institution of Biomedicine, Gothenburg University, Box 413, S- 405 30, Gothenburg, Sweden
  2. Childhood Cancer Research Unit, Karolinska Institute, Astrid Lindgren Children’s Hospital, Q6:05, S-171 76, Stockholm, Sweden
  3. Department of Medical Biology, University of Troms?, Troms?, Norway
  4. Department of Mathematical Statistics, Chalmers University of Technology, Gothenburg, Sweden
  5. Department of Pediatric Oncology, Clinical Sciences, Lund University, Lund, Sweden
  6. Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
  7. Department of Cancer Genetics, Royal College of Surgeons in Ireland and Children’s Research Centre, Our Lady’s Children’s Hospital, Dublin, Ireland
  8. Children’s Hospital of Philadelphia, Division of Oncology, The University of Pennsylvania, Philadelphia, PA, USA
  9. Department of Oncogenomics, Academic Medical Center, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands
  
• ISSN：1476-4598

文摘

Background Neuroblastoma (NB) tumours are commonly divided into three cytogenetic subgroups. However, by unsupervised principal components analysis of gene expression profiles we recently identified four distinct subgroups, r1-r4. In the current study we characterized these different subgroups in more detail, with a specific focus on the fourth divergent tumour subgroup (r4). Methods Expression microarray data from four international studies corresponding to 148 neuroblastic tumour cases were subject to division into four expression subgroups using a previously described 6-gene signature. Differentially expressed genes between groups were identified using Significance Analysis of Microarray (SAM). Next, gene expression network modelling was performed to map signalling pathways and cellular processes representing each subgroup. Findings were validated at the protein level by immunohistochemistry and immunoblot analyses. Results We identified several significantly up-regulated genes in the r4 subgroup of which the tyrosine kinase receptor ERBB3 was most prominent (fold change: 132-40). By gene set enrichment analysis (GSEA) the constructed gene network of ERBB3 (n = 38 network partners) was significantly enriched in the r4 subgroup in all four independent data sets. ERBB3 was also positively correlated to the ErbB family members EGFR and ERBB2 in all data sets, and a concurrent overexpression was seen in the r4 subgroup. Further studies of histopathology categories using a fifth data set of 110 neuroblastic tumours, showed a striking similarity between the expression profile of r4 to ganglioneuroblastoma (GNB) and ganglioneuroma (GN) tumours. In contrast, the NB histopathological subtype was dominated by mitotic regulating genes, characterizing unfavourable NB subgroups in particular. The high ErbB3 expression in GN tumour types was verified at the protein level, and showed mainly expression in the mature ganglion cells. Conclusions Conclusively, this study demonstrates the importance of performing unsupervised clustering and subtype discovery of data sets prior to analyses to avoid a mixture of tumour subtypes, which may otherwise give distorted results and lead to incorrect conclusions. The current study identifies ERBB3 as a clear-cut marker of a GNB/GN-like expression profile, and we suggest a 7-gene expression signature (including ERBB3) as a complement to histopathology analysis of neuroblastic tumours. Further studies of ErbB3 and other ErbB family members and their role in neuroblastic differentiation and pathogenesis are warranted.